Fimasartan
Clinical data | |
---|---|
Trade names | Kanarb |
ATC code | |
Identifiers | |
| |
JSmol) | |
| |
|
Fimasartan is a non-peptide
Mechanism of action
Fimasartan acts on the kidney's rennin-angiotensin cascade, which begins when
In blocking the AT1 receptor, fimasartan inhibits vasoconstriction, favouring vasodilation. At the kidney and adrenal gland, AT1 blockage and prevention of aldosterone formation increase excretion of water and salt by the kidneys, which decreases overall blood volume.[7] At the heart, AT1 blockage decreases contractility and the stimulatory effects of the sympathetic nervous system.[4] Collectively, fimasartain leads to a reduction in blood pressure and alleviation of hypertensive symptoms. ARBs like fimasartan have also shown to be protective against
Side effects
Side effects In clinical trials, fimasartan was well tolerated in all patients. However, higher dosing (360 mg/day) was accompanied by increased dizziness (most likely due to the momentary decrease in blood pressure) and headaches in a low number of patients.[1] Other side effects such as diarrhea, syncope, and cold feet were also experienced in a low number of subjects, which all resolved without medical intervention.[1]
Pharmacology
Fimasartan is rapidly absorbed and has minimal accumulation in the body 7 days after administration.[1] Fimasartan possesses a half-life of 9 to 16 hours,[1] appropriate for daily dosing. Fimasartan was found to be effective in fasted or fed states, with a variety of dosing regimens. In trials, the maximum effects of the drug occurred slightly after the maximum plasma concentration (T-max) was achieved,[1] which occurs 30 minutes to 3 hours after dosing.[12] Fimasartan was found mostly in unmetabolized form in the plasma and in bile excretions. Urinary elimination of the drug was low, at less than 3% 24 hours after administration, entailing that the fimasartan does not undergo renal excretion.[1]
Society and culture
Brand names
The drug is also available in Russia as Канарб (Kanarb).[13] Fimasartan is being marketed in India under the brand name of Fimanta and Fimagen through Ajanta Pharma Ltd.
References
- ^ S2CID 3067660.
- PMID 31463228.
- ISBN 978-1-60761-186-8.
- ^ PMID 21740078.
- PMID 11171802.
- PMID 20161229.
- ^ Klabunde RE (15 March 2007). "Angiotensin Receptor Blockers (ARBs)". CV Pharmacology.
- S2CID 46148907.
- ^ PMID 10562266.
- S2CID 27296727.
- PMID 9737942.
- PMID 22727611.
- ^ "Kanarb (fimasartan) film-coated tablets. Registration Certificate". Russian State Register of Medicines (in Russian). JSC R-Pharm. Retrieved 1 September 2020.